Treatment outcomes of direct-acting antiviral (DAA) therapy among chronic kidney disease (CKD) and post kidney transplant patients with hepatitis c virus (HCV) infection: Single center experience

Author(s): Capucion, Shena Jo A, Jamias, and Jade D

Hepatitis C virus (HCV) infection is common among chronic kidney disease (CKD) and kidney transplant recipients. Direct acting antiviral (DAA) regimens has been demonstrated to be effective with high sustained virological response (SVR) rates and tolerated in the general population. Data is limited and remains to be confirmed among CKD and kidney transplant recipients. Kidney transplantation or renal transplantation is the organ relocate of a kidney into a patient with end-stage kidney illness. Kidney transplantation is ordinarily delegated expired benefactor (some time ago known as cadaveric) or living-giver transplantation relying upon the wellspring of the contributor organ.